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Background: The 22q11.2 deletion syndrome confers a 
markedly increased risk for schizophrenia. 22q11.2 deletion 
carriers without manifest psychotic disorder offer the possi-
bility to identify functional abnormalities that precede clini-
cal onset. Since schizophrenia is associated with a reduced 
cortical gamma response to auditory stimulation at 40 
Hz, we hypothesized that the 40 Hz auditory steady-state 
response (ASSR) may be attenuated in nonpsychotic indi-
viduals with a 22q11.2 deletion. Methods: Eighteen young 
nonpsychotic 22q11.2 deletion carriers and a control group 
of 27 noncarriers with comparable age range (12–25 years) 
and sex ratio underwent 128-channel EEG. We recorded 
the cortical ASSR to a 40 Hz train of clicks, given either 
at a regular inter-stimulus interval of 25 ms or at irregular 
intervals jittered between 11 and 37 ms. Results: Healthy 
noncarriers expressed a stable ASSR to regular but not in 
the irregular 40 Hz click stimulation. Both gamma power 
and inter-trial phase coherence of the ASSR were markedly 
reduced in the 22q11.2 deletion group. The ability to phase 
lock cortical gamma activity to regular auditory 40 Hz 
stimulation correlated with the individual expression of neg-
ative symptoms in deletion carriers (ρ = −0.487, P = .041). 
Conclusions: Nonpsychotic 22q11.2 deletion carriers lack 
efficient phase locking of evoked gamma activity to regu-
lar 40 Hz auditory stimulation. This abnormality indicates 
a dysfunction of fast intracortical oscillatory processing in 
the gamma-band. Since ASSR was attenuated in nonpsy-
chotic deletion carriers, ASSR deficiency may constitute a 
premorbid risk marker of schizophrenia.
Key words:  22q11.2 deletion syndrome/gamma band/ 
EEG/oscillations/schizophrenia
Introduction
The 22q11.2 deletion is the most common copy num-
ber variant in humans with an estimated prevalence of 
1:2000 to 1:4000.1–3 22q11.2 deletions are associated with 
a highly variable clinical phenotype, including a range of 
somatic disorders, learning problems, cognitive deficits,4,5 
and hearing loss.6 Individuals carrying a 22q11.2 dele-
tion have an increased risk of developing schizophrenia 
and other psychiatric disorders such as autism spectrum 
disorder and attention deficit hyperactivity disorder.7–9 
According to the International Consortium on Brain and 
Behavior in 22q11.2 Deletion Syndrome (22q11.2DS), 
the prevalence of schizophrenia-spectrum disorder is 
24% in adolescent and 41% in adult 22q11.2 carriers.8 
A recent nationwide Danish Registry study showed that 
the risk of developing a schizophrenia-spectrum disorder 
in individuals previously diagnosed with 22q11.2DS was 
approximately 8 times higher than in the general popu-
lation.10 Since the 22q11.2DS confers a substantial risk 
for schizophrenia, the identification of neurophysiologic 
abnormalities in nonpsychotic 22q11.2 deletion carri-
ers may reveal important insights into the pathogenesis 
of schizophrenia and assist the search of early markers. 
Investigations of high-risk groups are very appealing 
from a clinical perspective as they not only can provide a 
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better knowledge of the disease evolution, but potentially 
can lead to strategies for prevention or early treatment.
Auditory steady-state responses (ASSRs) evoked by 
brief tones or clicks at a repetition rate of 40 Hz provide a 
readily available, noninvasive means of probing impaired 
neural gamma synchrony in the auditory system.11 A sem-
inal ASSR study showed that the ASSR was selectively 
reduced in patients with schizophrenia when auditory 
stimulation was applied at 40 Hz, but not at 20 Hz or 30 
Hz.12 Later studies reported reduced expression and phase 
locking of steady-state gamma oscillations in patients 
with schizophrenia.13–16 A recent meta-analysis concludes 
that decreased 40 Hz ASSR is a robust finding in schizo-
phrenia.17 The ASSR is further observed reduced in first-
episode psychosis,18,19 as well as in nonaffected first degree 
relatives.20,21 So far, there have been no studies looking 
at ASSR in 22q11.2DS. However, one study has shown 
reduced ASSR in an ultra-high-risk group (UHR),22 where 
subjects who met criteria for attenuated psychotic symp-
toms, brief intermittent psychotic symptoms and genetic 
risk deterioration were included in the study based on the 
structured interview for prodromal symptoms (SIPS).
Linking ASSR and clinical symptoms in schizophrenia, 
inter-trial phase coherence (ITPC) has shown to be positive 
correlated with the presence of positive symptoms.19 The 
same group also reported a positive correlation between 
left-hemispheric ITPC and the expression of auditory hal-
lucination.15 Moreover, a negative correlation between the 
ASSR amplitude at 80 Hz and negative symptoms has been 
shown.23 In the UHR-study,22 the power of the ASSR at 40 
Hz was negatively correlated with the individual PANSS 
scores for positive symptoms, but not for negative symptoms.
In schizophrenia, impaired neural processing in cor-
tical circuits has been attributed to dysfunctional oscil-
latory cortical activity in the gamma-band (30–100 Hz) 
and underlying abnormalities in GABAergic and gluta-
matergic neurotransmission.12,24–26 Cortical gamma oscil-
lations rely on the integrity of fast-spiking GABAergic 
interneurons which exert a finely timed inhibition onto 
the pyramidal cells and other inhibitory interneurons.27–29 
Disturbed interactions of these circuits are thought 
to critically contribute to pathogenesis and cognitive 
impairment in schizophrenia.30,31 In agreement with the 
notion of a GABAergic dysfunction, magnetic resonance 
spectroscopy revealed that gamma-aminobutyric acid 
(GABA) levels in visual cortex are reduced by 13% in 
patients with schizophrenia as compared to healthy con-
trols.32 Likewise, prefrontal GABA levels were reduced in 
patients with schizophrenia as compared to controls using 
magnetic resonance spectroscopy at 7 T.33 Accordingly, 
postmortem studies of 22q11.2 carriers have shown 
reduced levels of GABA34 at cites of cortical malfunc-
tion. Recent studies have provided converging evidence 
that cortical gamma oscillatory activity critically depend 
on the function of N-methyl-D-aspartate (NMDA) 
receptors located on parvalbumin-positive, fast-spiking, 
GABAergic interneurons.35–40 The emerging links between 
abnormal cortical gamma oscillatory activity and specific 
cellular and subcellular mechanisms constitute a poten-
tial target for future treatments of schizophrenia.24,28,41
In murine models of  22q11.2DS, a disruption of  glu-
tamatergic synaptic transmission within the auditory 
cortex has been found.42 Further, in a mouse model of 
22q11.2DS increased acoustic startle response as well 
as prepulse inhibition (PPI) deficits was found.43 Since 
no difference in auditory brain stem responses were 
found, the deficits in PPI could not account for this. 
One study investigated auditory gating in 22q11.2DS.44 
While P50 was found to be normal, 22q11.2DS carriers 
showed increased amplitudes of  the first N1 component 
at central electrodes, suggesting abnormal higher order 
processing.
Using a neurogenetically informed approach, we 
recorded the ASSR in nonpsychotic carriers of a 22q11.2 
deletion and healthy controls without such deletion 
with comparable age range and sex ratio. The auditory 
stimulation was applied regularly and irregularly, testing 
whether temporal regularity of the 40 Hz train was criti-
cal to evoke ASSR. In this way, we could test for differ-
ences in steady state as well as transient (nonsteady state) 
responses. We expected that the 22q11.2 deletion carri-
ers express a reduced cortical gamma response to regular 
auditory stimulation at 40 Hz as a potential risk marker 
of schizophrenia, showing a reduction in power and 
reduced phase synchronization of the ASSR relative to 
healthy noncarriers. Further, we expected the response to 
irregular stimulation to be matched between groups. We 
further explored whether the ASSR alterations in 22q11.2 
deletion carriers were correlated with symptom severity.
Materials and Methods
Subjects
Eighteen young individuals 12–25  years with a verified 
3 MB deletion at chromosome 22q11.2 and 27 healthy 
individuals without a 22q11.2 deletion participated in 
the study. Groups were comparable with respect to sex 
ratio (controls: 18 males and 9 females, carriers: 13 males 
and 5 females, χ2 = 0.54, P =  .46) and age distribution 
(controls: mean age  =  15.96  years, standard deviation 
(SD)  =  2.71  years; carriers: mean age  =  15.39  years, 
SD = 2.45 years, t43 = 0.72, P = .47). All participants were 
evaluated for the presence of current psychiatric disor-
ders and diagnoses were given according to the ICD-10 
diagnostic system if  clinical criteria were met. For more 
information on diagnose criteria, see supplementary 
material. Carriers of the 22q11.2 deletion with a known 
history of schizophrenia were excluded. The Structured 
Interview for Prodromal Syndromes (SIPS)45,46 was used 
to rate the severity of: positive, negative, disorganized, 
and general symptoms, see supplementary materials for 
detailed information.
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The following exclusion criteria were applied to con-
trols: (a) schizophrenia, schizotypical and delusional dis-
orders (ICD10 DF20-29); (b) bipolar disorder (ICD10 
DF30-31); (c) depression (ICD10 DF32-33) except for 
a past episode of mild or moderate depression (ICD10 
DF 32.0 or 32.1); (d) substance abuse; or (e) a first degree 
relative with a psychotic illness. All participants under-
went a verbal and written informed consent process. 
Participants under the age of 18 provided a verbal assent 
while their parent’s completed written consent. The study 
was approved by the Regional Ethical Committee of 
Copenhagen (project id: H-3-2012-136) and the Danish 
Data protection Agency (project id: 2007-58-0015). 
All participants are part of a larger nationwide study 
and underwent extended cognitive, genetic, and clini-
cal testing, described in detail by Schmock et al.47 Since 
22q11.2DS is associated with hearing loss, audiometric 
testing was performed prior to the experiment to confirm 
that participants were able to hear the click stimuli (20 dB 
random test Oscilla USB-310 Tablet screening audiom-
eter), see supplementary materials for more details.
ASSR Paradigm
To evoke steady-state gamma activity, subjects were pre-
sented with a train of short clicks delivered at a mean 
click-repetition frequency of 40 Hz.12 Each click lasted 
1 ms and each click train lasted 1 s, followed by a pause 
of 2  s, resulting in a stimulus onset asynchrony of 3  s 
(figure  1). The stimuli were delivered binaurally via 
insert-earphones at a sound pressure level of 85 dB (E-A-
RTONE 3A), using the MatLab-based Cogent 2000 
toolbox as presentation software (http://www.vislab.ucl.
ac.uk/cogent_2000.php). We used an external soundcard 
(RME Babyface 22-Channel, 192  kHz Bus-powered, 
Haimhausen, Germany). During ASSR recording, sub-
jects sat in a comfortable chair, were instructed to relax 
and to constantly look at a fixation cross on the screen in 
front of them without paying particular attention to the 
sounds.
We applied regular and irregular 40 Hz trains. In the 
regular condition, clicks had a constant inter-click inter-
val of 25  ms (ie, regular 40 Hz train). In the irregular 
condition, the inter-click interval was randomly jittered 
between 11 and 37 ms while maintaining a mean click fre-
quency of 40 Hz. We introduced this condition to record 
the cortical response evoked by click stimulation that was 
matched for all acoustic features except regularity. Thus, 
the irregular condition served as a control condition test-
ing whether the temporal regularity of the 40 Hz train 
was critical to evoke abnormal auditory cortical process-
ing restricted to ASSR. The temporal structure of the 
irregular click train was kept constant within subjects, 
but changed randomly across subjects. For regular and 
Fig. 1. Temporal structure of the auditory stimulation paradigm to evoke 40 Hz auditory steady-state responses. Regular (run 1) and 
irregular (run 2) 40 Hz click trains were given in separate experimental blocks. Each click train had duration of 1 s, followed by a pause 
of 2 s. Clicks were applied every 25 ms at a constant frequency of 40 Hz in the regular condition and randomly jittered from 11 to 37 ms 
in the irregular condition. An epoch covered the period of 40 Hz stimulation and a peristimulus window of −1000 to 2000 ms.
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irregular 40 Hz stimulation, ASSR were recorded in 2 
separate runs, consisting of 120 trials (figure 1). A single 
run lasted 6 min.
EEG Recordings and Preprocessing
EEG data was recorded using a 128 channel ActiveTwo 
Biosemi System (BioSemi, Amsterdam, Netherlands) at a 
sampling frequency of 4096 Hz. Preprocessing and anal-
ysis were carried out using the fieldtrip toolbox.48 The 
preprocessing steps consisted of referencing to the aver-
age of the 2 mastoids, band-pass filtering using the inter-
val [1–130] Hz, notch filtering using the interval [48–52] 
Hz to attenuate 50 Hz line noise, down-sampling to 1024 
Hz, and finally epoching with a peri-stimulus window of 
−1000 to 2000 ms. Epochs were baseline corrected using 
the average over the time window −1000 to −300  ms. 
Artifact removal was performed using a simple thresh-
old approach where epochs were rejected if  their values 
exceeded ±100 µV. No channels were discarded.
Time-Frequency Analysis
The epoched data were wavelet-transformed using a 
Complex Morlet wavelet with 12 cycles, as implemented 
in the Fieldtrip toolbox.48 The frequency band of interest 
covered frequencies from 10 to 60 Hz at 1 Hz resolution. 
The inter-trial phase coherence (ITPC) and power were 
extracted from the wavelet coefficients. The amplitude of 
the ITPC reflects the phase consistency across trials for a 
given channel, time and frequency point and can take val-
ues between 0 (no phase consistency) and 1 (perfect phase 
consistency). The ITPC and power amplitude as recorded 
from Cz were averaged in the 300–700 ms time window of 
auditory stimulation over the frequencies 36–44 Hz.
Statistical Analysis
Two sample t-test and Wilcoxon rank sum test was 
used to test for case–control differences in IQ and the 4 
domain scores obtained from the SIPS interview, respec-
tively. Group differences in ASSR were assessed using a 
hypothesis-driven approach testing for differences in raw 
ITPC amplitude as well as power values between groups 
from one single EEG channel (Cz according to the inter-
national 10-20 system, see figure 2 where channel Cz is 
marked). We chose Cz because we had a priori knowl-
edge that the sensors of the mid-central regions express 
the highest gamma response to regular click stimulation 
at 40 Hz.49 Two separate repeated-measures analysis of 
covariance (rm-ANCOVA) were therefore computed 
with ITPC or power as dependent variables. The rm-
ANCOVA included the factors group (2 levels: deletion 
carriers and noncarriers) and the within-subject factor 
condition (2 levels: regular and irregular), as well as age 
and sex as covariates. We post hoc added hearing thresh-
olds observed as a mean over frequencies from the 20 dB 
random test as covariate. Information regarding post hoc 
test for diagnosis and IQ can be found in the supplemen-
tary material.
Greenhouse-Geisser correction for nonsphericity was 
applied if  necessary. Follow-up t-tests were performed 
for significant interactions. If  equality of variance where 
not met (assessed with Levene’s test), separate variance 
t-tests were performed when necessary. Bonferroni cor-
rection for multiple comparisons was applied if  necessary 
and significance levels were corrected accordingly.
Two subjects belonging to the 22q11.2 group com-
pleted only the regular condition because of exhaustion 
after this session. One healthy noncarrier had to be dis-
carded from the regular condition due to problems with 
the trigger. The results are thus based on the ASSR of 
18 deletion carriers for the regular condition, 16 deletion 
carriers for the irregular condition, 26 healthy noncarri-
ers for the regular condition and 27 healthy noncarriers 
for the irregular condition. For the rm-ANCOVA the 
results are based on 16 deletion carriers and 26 nondele-
tion carriers.
Nonparametric Spearman’s rank correlations analysis 
was performed to test for correlations between individual 
ASSR measures and negative symptoms score. Only cor-
relations with negative symptoms were carried out since 
the presentation of positive, disorganized and generalized 
symptoms were skewed in the present group (5 out of 18 
(28%) of the 22q11.2 deletion carriers had a score of 0 in 
the positive symptoms, 5 out of 18 (28%) in the disorga-
nized and 11 out of 18 (61%) in generalized symptoms). 
For all analyses, significance threshold was set at P < .05.
Results
The 22q11.2DS group had an IQ (median  =  82.0, 
90th percentile = 94.8, 10th percentile = 63.6) that was 
significantly lower than the IQ in the control group 
(median  =  108.0, 90th percentile  =  127, 10th percen-
tile = 95.2, t43 = −7.05, P < .001). The included raw sum 
of negative symptoms for the 22q11.2 carriers ranged 
from 1 to 16 (mean = 7 and SD = 3.5), from 0 to 12 for 
positive symptoms (mean = 2.7, SD = 3.1), from 0 to 6 for 
disorganized (mean = 1.8, SD = 1.8) and from 0 to 7 for 
generalized symptoms (mean = 1.0, SD = 1.9).
Within the 22q11.2 deletion carriers, one was diag-
nosed with affective disorder, 2 with disturbance of activ-
ity/attention deficit disorder without hyperactivity, 6 with 
anxiety or phobia and one with both autism spectrum 
disorder and anxiety or phobia. None of the participants 
had psychosis, but the 22q11.2DS cohort had significantly 
elevated raw SIPS scores for negative (W = 477, P < .001), 
positive (W = 350.5, P = .008), disorganized (W = 404, 
P < .001) and generalized (W = 312.5, P = .027) symp-
toms, relative to the control group. Fifteen of the 22q11.2 
deletion carriers had negative symptoms within the 
attenuated level (3–5) in one or more of the negative 
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symptoms categories, but only 3 individuals had one or 
more psychotic and/or disorganized symptoms within the 
attenuated level. Generalized symptoms at the attenuated 
level were only seen in 2 of the 22q11.2 deletion carriers. 
Apart from one subject taking 20 mg of retalin, none of 
the carriers took medication acting on the central ner-
vous system.
The 20 dB random test, revealed that subjects were able 
to detect the tones used for eliciting ASSR. Across fre-
quencies the observed threshold levels were (mean = 20.5, 
SD = 0.7) for controls and (mean = 24.6, SD = 3.6) for 
22q11.2. In 2 22q11.2 deletion carriers, the dB level of the 
click trains was decreased from 85 dB to 80 dB because 
they reported that the stimulus was uncomfortable at 
85 dB.
Mean ITPC and power frequency plots of the ASSR 
for healthy 22q11.2 deletion carriers and noncarriers are 
shown in figures 2A and 2B, respectively. Healthy controls 
without a 22q11.2 deletion showed a clearly discernible 
ASSR at around 40 Hz which was temporally confined 
to the time of regular click stimulation (figure  2). This 
response critically relied on the regularity of the 40 Hz 
acoustic train, because jittering the frequency around 
40 Hz, as expected reduced the ASSR (figures 2 and 3). 
Nonpsychotic carriers showed a clear attenuation of 
the ASSR to regular 40 Hz click stimulation (figures 2 
and 3) when comparing to the healthy noncarriers. The 
response to the irregular 40 Hz click train stimulation was 
similar in both groups.
Inter-trial Phase Coherence
Repeated-measures-ANCOVA revealed that mean 
ITPC across the 2 conditions was significantly lower for 
the 22q11.2 group compared to the noncarrier group 
(F1,38 = 7.1, P = .011, figure 3A). Moreover, we observed a 
significant effect of condition (F1,38 = 6.3, P = .016), showing 
that the regular condition was overall much more effective 
Fig. 2. Group time frequency plots of the ASSR within the 10–60 Hz range from electrode Cz. (A) Group ITPC of the ASSR for the 
regular (top) and irregular (bottom), for both noncarriers (left) and 22q11.2 carriers (right). (B) Group power of the ASSR, again shown 
for both conditions and groups. In both (A) and (B), the time stamp 0 indicates the onset of the click train. Duration of the click train is 
illustrated by the grey box. In the time-frequency response a cut-off  can be seen (ie, white area without data in the color plots) due to the 
length of the wavelet being longer for the lower frequencies as compared to higher frequencies. Consequently, not all time point values 
can be estimated. (C) Topographical maps for ITPC presented for controls, 22q11.2 and both conditions as in A in the time window 
300–700 ms and frequency window 36–44 Hz. (D) Topographical maps for power presented for controls, 22q11.2 and both conditions as 
in B in the time window 300–700 ms and frequency window 36–44 Hz.
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than the irregular. There was no significant group-by-con-
dition interaction (F1,38 = 2.4, P = .127). Overall the mean 
value of ITPC in the regular condition was reduced by 28% 
in the deletion carriers compared to the noncarriers and by 
21% in the irregular condition (figure 3A). ITPC decreased 
with age (F1,38 = 6.4, P = .016) and age showed a significant 
interaction with condition (F1,38 = 4.7, P = .037) attribut-
able by younger participants having a higher ITPC score in 
the regular condition compared to older participants while 
younger and older participants showed similar values for the 
irregular condition. No effect of sex (F1,38 = 2.0, P = .169) 
or interaction (condition-by-sex, F1,38 = 1.6, P = .209) was 
observed. Adding hearing threshold as covariates the group 
effect did not change significance.
Power
Repeated-measures-ANCOVA also showed a significant 
group difference in power (F1,38  =  7.6, P  =  .009) which 
reflected a relative reduction of the ASSR power in dele-
tion carriers (figure 3B). There was also a main effect for 
condition (F1,38 = 4.6, P = .038) and a significant interaction 
between group and condition (F1,38 = 6.1, P = .018) which 
was due to a stronger decrease in power for the regular con-
dition in deletion carriers relative to noncarriers (figure 3B). 
Post hoc pair-wise comparisons confirmed that 22q11.2 
deletion carriers had a lower power for the regular condi-
tion as compared to healthy noncarriers (t40 = 2.4, P = .022, 
α = 0.025), while power did not differ from healthy non-
carriers in the irregular condition (t40  =  2.9, P  =  .770). 
Overall the mean value of power in the regular condition 
was reduced by 24% in the deletion carriers compared to 
the noncarriers, but only by 4% in the irregular condition.
We also found a significant effect for age with lower 
ASSR power at higher age (F1,38  =  5.7, P  =  .022). The 
age effect interacted with condition (F1,38 = 5.3, P = .027). 
Inspection of the individual data revealed that younger 
participants expressed a higher power in the regular con-
dition compared to older participants, while power was 
not influenced by age in the irregular condition. There 
was no effect of sex (F1,38 = 0.8, P = .368) or interaction 
between sex and condition observed (F1,38 = 1.2, P = .283).
For post hoc tests on diagnosis and IQ, see supplemen-
tary material.
Correlation With Negative Symptoms
In carriers with a 22q11.2 deletion, individual ITPC 
for the regular condition showed a negative correlation 
with the individual SIPS scores of negative symptoms 
Fig. 3. Group data of the ASSR. Mean ITPC (A) and mean gamma power (B) of the ASSR evoked by regular or irregular 40 Hz click 
trains in 22q11.2 carriers (light gray) and healthy noncarriers (dark gray). Asterisks indicate significant between-group difference  
(*P < .05, **P < .01). Error bars equal SEM (standard error of the mean). (C) and (D) shows ITPC and power as a function of SIPS 
negative subscale scores, respectively. Since the nonparametric spearman rank correlation was used, there is no regression line.
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(Spearman: ρ  =  −0.487, P  =  .041). The correlation 
remained significant after including age as covariate 
(ρ = −0.493 P = .045). For comparison, we also calculated 
the correlation between ITPC for the irregular condition 
and negative symptom scores and found no correlation 
(ρ = −0.146, P = .591). No correlation was found between 
ASSR power and negative symptom scores (Spearman: 
ρ = −0.245 P = .326).
Discussion
This study, to our knowledge, provides first-time evidence 
that the cortical steady-state response to auditory 40 Hz 
stimulation is impaired in a genetically defined group with 
a markedly increased risk for schizophrenia. In nonpsy-
chotic 22q11.2 deletion carriers, the gamma power of the 
ASSR was significantly reduced by 24% during regular 40 
Hz click stimulation relative to healthy controls without 
22q11.2 deletion. We further detected a reduced phase 
precision of the ASSR in nonpsychotic 22q11.2 deletion 
carriers who showed on average a relative reduction of 
28% in trial-to-trial phase synchronization as compared 
to the control group. The ability to phase lock the audi-
tory evoked gamma activity to the 40 Hz click train 
stimulation was negatively correlated with the negative 
symptom scores of the 22q11.2 carriers. The results con-
firm and extend previous ASSR studies in nonpsychotic 
first-degree relatives of patients with schizophrenia.20,21 
Together, these findings show that a deficient ASSR may 
be a useful premorbid risk marker for schizophrenia. In 
carriers with a 22q11.2 deletion, reduced trial-to-trial 
phase synchronization correlated with the presence of 
elevated negative symptoms. Since negative symptoms 
represent an important facet of the symptomatology in 
schizophrenia these findings corroborate the notion that 
abnormal synchronization of gamma-band activity may 
play an important role in the generation of the negative 
symptoms in schizophrenia.
GABAA receptor-mediated inhibition plays a substan-
tial role in the underlying mechanisms of gamma oscil-
lations.50 GABA-mediated inhibition results in decreased 
gamma oscillations and cognitive impairment, for a review 
see.30,51 Recent studies in rodents point to a critical func-
tional role of NMDA receptors located on fast-spiking 
parvalbumin positive, GABAergic interneurons39,40,52,53 in 
the generation of cortical gamma oscillations, suggest-
ing that the ASSR may be used as biomarker for cortical 
NMDA function.37
The ASSR is reduced in schizophrenia14–16 as well as 
in first-episode psychosis.18,19 This might be caused by a 
reduced concentration of GABA or dysfunctional GABA 
release24,54 or a dysfunction of the NMDA receptors con-
trolling the fast-spiking GABAergic interneurons.55 In 
addition, electrophysiological findings have indicated that 
evoked gamma power increases during childhood and 
adolescence.56–58 It is thus believed that neural synchrony 
continues to develop until early adulthood,58 which might 
be linked to a gradual developmental switch in expres-
sion of the gamma-1 relative to the gamma-2 subunit of 
the GABA receptors, causing a more rapid and precise 
inhibition of pyramidal target cells.59 It therefore remains 
to be clarified, whether the abnormal ASSR in 22q11.2 
deletion carriers is caused by a GABA-related or NMDA 
receptor related dysfunction or both.
Although we speculate that the present finding of a 
reduced ASSR in 22q11.2 deletion carriers could be due 
to a reduced level of GABA as observed in schizophre-
nia, 22q11.2DS results in a wide range of neurobiological 
abnormalities. Other neurobiological sequelae, such as 
hearing loss,6 PRODH deletion effects on glutamatergic 
transmission,60 and ZDHHC8 deletion effects on devel-
opment of neural function,60,61 might also affect the ASSR 
in 22q11.2 deletion carriers. At variance with 2 previous 
reports,56,57 we found that the power and ITPC of ASSR 
decreased with age. However, the age range in the pres-
ent study (12–25 years, with the majority being between 
12 and 18 years) differs markedly from the age ranges in 
previous reports. In one study, 3 groups were tested at 
an age of 10, 11.5, and 19–45 years.56 In a MEG study 
on the age effect on ASSR, age distribution was large, 
ranging from 5 to 52 years.57 Since our statistical analysis 
revealed group differences in ITPC and power in a model 
that controlled for the effect of age, the observed abnor-
mality in ASSR in deletion carriers cannot be attributed 
to the age of our participants. Since it can be expected 
that a proportion of 22q11.2 carriers will develop schizo-
phrenia at a later time in life,8 repeated measurements of 
ASSR in the same subjects during adolescence and early 
adulthood might provide more fine-grained insights into 
age-related developmental trajectories of ASSR abnor-
malities and their relation to the clinical manifestation of 
schizophrenia.
The reduction of ITPC in 22q11.2 deletion carriers was 
observed across the 2 conditions; regular and irregular. 
However, the reduction of power was observed only in 
the regular condition. This is an interesting finding, show-
ing that even transient gamma responses during irregu-
lar broad-band gamma stimulation are less efficiently 
aligned in deletion carriers. ITPC correlated negatively 
with the negative symptoms of the 22q11.2 deletion car-
riers. However, given the exploratory nature of the corre-
lational analyses and the relatively small sample size this 
finding should be considered preliminary and needs to be 
replicated in larger studies before any strong conclusions 
can be drawn. The small sample size of nonpsychotic 
22q11.2 deletion carriers is a limitation of the study. The 
abnormalities in ASSR found in 18 deletion carriers war-
rant replication in larger cohorts.
In conclusion, this study presents first time evidence 
that young nonpsychotic 22q11.2 carriers lack the audi-
tory steady state gamma response. This highlights the 
emerging importance of  gamma-band oscillations in 
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understanding the neurophysiological characteristics of 
schizophrenia. Further, the observed results in a non-
psychotic high risk group indicate that dysfunctional 
gamma responses from an auditory steady state gamma 
paradigm could potentially serve as an early risk marker 
for schizophrenia if  confirmed by longitudinal studies. 
Reliable functional risk markers that can support early 
diagnostics may assist clinical decision-making for tar-
geted therapy. This is relevant because recent results 
found a positive effect of  early treatment on clinical and 
function status.62,63
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